151 related articles for article (PubMed ID: 19651322)
1. Ranibizumab and nonocular hemorrhage.
Beaumont PE; Kang HK
Ophthalmology; 2009 Aug; 116(8):1593. PubMed ID: 19651322
[No Abstract] [Full Text] [Related]
2. Necessity of paracentesis before or after intravitreal injection of bevacizumab.
Huang WC; Lin JM; Chiang CC; Tsai YY
Arch Ophthalmol; 2008 Sep; 126(9):1314-5; author reply 1315. PubMed ID: 18779502
[No Abstract] [Full Text] [Related]
3. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study.
Brown DM; Michels M; Kaiser PK; Heier JS; Sy JP; Ianchulev T;
Ophthalmology; 2009 Jan; 116(1):57-65.e5. PubMed ID: 19118696
[TBL] [Abstract][Full Text] [Related]
4. Erratum: Ranibizumab and Nonocular Hemorrhage.
Beaumont PE; Kang HK
Ophthalmology; 2010 Aug; 117(8):1662-3; author reply 1663-4. PubMed ID: 20712066
[No Abstract] [Full Text] [Related]
5. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study.
Heier JS; Boyer DS; Ciulla TA; Ferrone PJ; Jumper JM; Gentile RC; Kotlovker D; Chung CY; Kim RY;
Arch Ophthalmol; 2006 Nov; 124(11):1532-42. PubMed ID: 17101999
[TBL] [Abstract][Full Text] [Related]
6. Photodynamic therapy with verteporfin combined with intravitreal injection of bevacizumab for exudative age-related macular degeneration.
Aggio FB; Melo GB; Höfling-Lima AL; Eid Farah M
Acta Ophthalmol Scand; 2006 Dec; 84(6):831-3. PubMed ID: 17083553
[No Abstract] [Full Text] [Related]
7. Improved vision-related function after ranibizumab vs photodynamic therapy: a randomized clinical trial.
Bressler NM; Chang TS; Fine JT; Dolan CM; Ward J;
Arch Ophthalmol; 2009 Jan; 127(1):13-21. PubMed ID: 19139332
[TBL] [Abstract][Full Text] [Related]
8. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results.
Antoszyk AN; Tuomi L; Chung CY; Singh A;
Am J Ophthalmol; 2008 May; 145(5):862-74. PubMed ID: 18321465
[TBL] [Abstract][Full Text] [Related]
9. Ranibizumab for the treatment of neovascular age-related macular degeneration: a review.
Kourlas H; Abrams P
Clin Ther; 2007 Sep; 29(9):1850-61. PubMed ID: 18035187
[TBL] [Abstract][Full Text] [Related]
10. Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials.
Barbazetto IA; Saroj N; Shapiro H; Wong P; Ho AC; Freund KB
Am J Ophthalmol; 2010 Jun; 149(6):939-946.e1. PubMed ID: 20378094
[TBL] [Abstract][Full Text] [Related]
11. Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone.
Augustin AJ; Puls S; Offermann I
Retina; 2007 Feb; 27(2):133-40. PubMed ID: 17290193
[TBL] [Abstract][Full Text] [Related]
12. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration.
Dhalla MS; Shah GK; Blinder KJ; Ryan EH; Mittra RA; Tewari A
Retina; 2006; 26(9):988-93. PubMed ID: 17151484
[TBL] [Abstract][Full Text] [Related]
13. Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration.
Lazic R; Gabric N
Ophthalmology; 2007 Jun; 114(6):1179-85. PubMed ID: 17544776
[TBL] [Abstract][Full Text] [Related]
14. Ranibizumab versus verteporfin for neovascular age-related macular degeneration.
Brown DM; Kaiser PK; Michels M; Soubrane G; Heier JS; Kim RY; Sy JP; Schneider S;
N Engl J Med; 2006 Oct; 355(14):1432-44. PubMed ID: 17021319
[TBL] [Abstract][Full Text] [Related]
15. Re: Verteporfin combination regimens in the treatment of neovascular age-related macular degeneration.
Nelson M
Retina; 2010 Feb; 30(2):380; author reply 380-1. PubMed ID: 20142719
[No Abstract] [Full Text] [Related]
16. Antiangiogenic therapy in neovascular age-related macular degeneration.
Lin RC; Rosenfeld PJ
Int Ophthalmol Clin; 2007; 47(1):117-37. PubMed ID: 17237677
[No Abstract] [Full Text] [Related]
17. Controversies in the treatment of wet age-related macular degeneration.
Moreno SF; Paloma JB
Am J Ophthalmol; 2008 May; 145(5):937; author reply 938. PubMed ID: 18435977
[No Abstract] [Full Text] [Related]
18. Intravitreal bevacizumab vs verteporfin photodynamic therapy for neovascular age-related macular degeneration.
Bashshur ZF; Schakal A; Hamam RN; El Haibi CP; Jaafar RF; Noureddin BN
Arch Ophthalmol; 2007 Oct; 125(10):1357-61. PubMed ID: 17923543
[TBL] [Abstract][Full Text] [Related]
19. Comparing ranibizumab with bevacizumab.
Biswas P; Sengupta S; Choudhary R; Home S; Paul A; Sinha S
Ophthalmology; 2011 Mar; 118(3):600-600.e2. PubMed ID: 21376243
[No Abstract] [Full Text] [Related]
20. A cost-effectiveness analysis of three treatments for age-related macular degeneration.
Gower EW; Cassard SD; Bass EB; Schein OD; Bressler NM
Retina; 2010 Feb; 30(2):212-21. PubMed ID: 19940805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]